Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma

Acta Neuropathologica

Volumn 127, Issue 5, 2014, Pages 731-745

  Hoffman, Lindsey M ^a   Donson, Andrew M ^a   Nakachi, Ichiro ^b   Griesinger, Andrea M ^a   Birks, Diane K ^c   Amani, Vladimir ^a   Hemenway, Molly S ^a   Liu, Arthur K ^c   Wang, Michael ^a   Hankinson, Todd C ^c   Handler, Michael H ^c   Foreman, Nicholas K ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Ependymoma; Immune; Pediatric; Recurrent

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CONTROLLED STUDY; EPENDYMOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTERIOR FOSSA; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; COHORT ANALYSIS; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFRATENTORIAL NEOPLASMS; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COHORT STUDIES; CYTOKINES; EPENDYMOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFRATENTORIAL NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84899898066     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1212-8     Document Type: Article

References (41)

1. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413(6857):732-738 (Pubitemid 33009951)
2. Arimappamagan A, Somasundaram K, Thennarasu K et al (2013) A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group. PLoS One 8(4):e62042
3. Ashburner M, Ball CA, Blake JA et al (2000) Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 25(1):25-29 (Pubitemid 30257031)
4. Bouffet E, Perilongo G, Canete A, Massimino M (1998) Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30(6):319-29 (discussion 329-31)
5. Choi C, Xu X, Oh JW, Lee SJ, Gillespie GY, Park H, Jo H, Benveniste EN (2001) Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res 61(7):3084-3091 (Pubitemid 32691958)
6. David N Louis, Ohgaki H (2007) WHO classification of tumours of the central nervous system [electronic resource]. World Health Organization
7. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4(5):P3
8. Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-De-Masters BK, Handler MH, Waziri AE, Wang M, Foreman NK (2009) Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 183(11):7428-7440
9. Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1):207-210 (Pubitemid 34679544)
10. Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ (2012) Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One 7(8):e43339
11. Foreman NK, Love S, Thorne R (1996) Intracranial ependymomas: analysis of prognostic factors in a population-based series. Pediatr Neurosurg 24(3):119-125 (Pubitemid 26255091)
12. Foreman NK, Love S, Gill SS, Coakham HB (1997) Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report. Neurosurgery 40(4):856-60 (discussion 860)
13. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2010) Phase I Trial of Lapatinib in Children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 28(27):4221-4227
14. Fouladi M, Stewart CF, Olson J et al (2011) Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 29(26):3529-3534
15. Gajjar A, Packer RJ, Foreman NK, Cohen K, Haas-Kogan D, Merchant TE, on behalf of the COG Brain Tumor Committee (2012) Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors. Pediatr Blood Cancer n/a-n/a
16. Goldwein JW (1990) Recurrent intracranial ependymomas in children survival, patterns of failure, and prognostic factors. Cancer 66:557-563
17. Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK (2013) Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. doi:10.4049/jimmunol.1301966
18. Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, Yagita H, Sato K, Okumura K (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37(6):1160-6 (discussion 1166-7)
19. Hoffman LM, Reed Plimpton S, Foreman NK, Stence NV, Hankinson TC, Handler MH, Hemenway MS, Vibhakar R, Liu AK (2013) Fractionated stereotactic radiosurgery for recurrent ependymoma in children. J Neurooncol. doi:10.1007/s11060-013-1259-3
20. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC (2008) Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 26(30):4921-4927
21. Johnson RA, Wright KD, Poppleton H et al (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466(7306):632-636
22. Kilday JP, Mitra B, Domerg C et al (2012) Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the children's cancer leukaemia group (CCLG), societe Francaise d'oncologie pediatrique (SFOP), and international society for pediatric oncology (SIOP). Clin Cancer Res 18(7):2001-2011
23. Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216(1):15-24
24. Korshunov A, Witt H, Hielscher T et al (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28(19):3182-3190
25. Lathia JD, Li M, Hall PE et al (2012) Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol 72(5):766-778
26. Nilsen TW, Baglioni C (1979) Mechanism for discrimination between viral and host mRNA in interferon-treated cells. Proc Natl Acad Sci USA 76(6):2600-2604 (Pubitemid 9213915)
27. Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5(4):557-572 (Pubitemid 41180205)
28. Parsa AT, Waldron JS, Panner A et al (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84-88 (Pubitemid 46067390)
29. Peiffer DA, Le JM, Steemers FJ et al (2006) High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 16(9):1136-1148 (Pubitemid 44320401)
30. Peyre M, Commo F, Dantas-Barbosa C et al (2010) Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS One 5(9):e12932
31. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157-173 (Pubitemid 43357943)
32. Robertson PL, Zeltzer PM, Boyett JM et al (1998) Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's cancer group. J Neurosurg 88(4):695-703 (Pubitemid 28145213)
33. Rodrigues JC, Gonzalez GC, Zhang L et al (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 12(4):351-365
34. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898):646-650
35. Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-DeMasters BK, Waziri A (2011) Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res 17(22):6992-7002
36. Vogt L, Schmitz N, Kurrer MO et al (2006) VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest 116(10):2817-2826 (Pubitemid 44511645)
37. Wani K, Armstrong TS, Vera-Bolanos E et al (2012) A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123(5):727-738
38. Waziri A (2010) Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 21(1):31-42
39. Witt H, Mack SC, Ryzhova M et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20(2):143-157
40. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6(6):1633-1636
41. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F (2004) A model based background adjustment for oligonucleotide expression arrays